Zacks Research Predicts Alkermes FY2027 Earnings

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research issued their FY2027 earnings per share estimates for shares of Alkermes in a report released on Wednesday, March 5th. Zacks Research analyst R. Department expects that the company will earn $1.15 per share for the year. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share.

ALKS has been the subject of several other reports. Mizuho boosted their price target on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. UBS Group raised shares of Alkermes from a “sell” rating to a “neutral” rating and upped their target price for the stock from $21.00 to $38.00 in a report on Tuesday. HC Wainwright reissued a “neutral” rating and issued a $46.00 price target on shares of Alkermes in a research note on Thursday, February 13th. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Alkermes in a research report on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price target for the company. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and an average target price of $38.33.

Alkermes Trading Down 1.8 %

NASDAQ:ALKS opened at $34.65 on Thursday. The stock has a 50 day moving average of $31.76 and a two-hundred day moving average of $29.58. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45. The firm has a market cap of $5.63 billion, a P/E ratio of 15.97, a price-to-earnings-growth ratio of 2.20 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 61,151 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $32.07, for a total transaction of $1,961,112.57. Following the completion of the transaction, the executive vice president now directly owns 47,576 shares in the company, valued at $1,525,762.32. This trade represents a 56.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Cato T. Laurencin sold 2,691 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. This represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 309,179 shares of company stock valued at $10,412,450 in the last quarter. Insiders own 4.89% of the company’s stock.

Hedge Funds Weigh In On Alkermes

Institutional investors have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Alkermes in the fourth quarter valued at approximately $3,273,000. Mackenzie Financial Corp raised its position in Alkermes by 9.0% in the 4th quarter. Mackenzie Financial Corp now owns 332,626 shares of the company’s stock valued at $9,566,000 after purchasing an additional 27,604 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Alkermes in the 4th quarter valued at about $98,000. Vise Technologies Inc. grew its position in shares of Alkermes by 16.2% during the fourth quarter. Vise Technologies Inc. now owns 19,801 shares of the company’s stock worth $569,000 after buying an additional 2,755 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. increased its stake in shares of Alkermes by 4.3% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 601,129 shares of the company’s stock worth $17,288,000 after buying an additional 25,000 shares during the period. 95.21% of the stock is owned by institutional investors and hedge funds.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.